Streetbeat News

ADIL

Adial Pharmaceuticals, Inc.

https://www.adialpharma.com

Industry

Biotechnology

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Open

1.15

Mkt cap

6.8M

Volume

270K

High

1.15

P/E Ratio

-0.27

52-wk high

4.17

Low

1.04

Div yield

N/A

52-wk low

0.77

Adial Pharmaceuticals has secured a new US patent, expanding its intellectual property protection for its lead drug candidate, AD04, aimed at treating alcohol use disorder. This patent enhances the precision medicine approach by covering additional genotype combinations identified through Adial's genetic diagnostic tool.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 12:30 pm

Adial Pharmaceuticals has expanded its patent estate, which covers its unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm

Adial Pharmaceuticals has received a Notice of Allowance for a U.S. patent covering expanded genotype combinations identified using its genetic diagnostic for addiction treatment. This development could enhance the company's intellectual property portfolio and potentially improve its market position in addiction treatment solutions.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm

Adial Pharmaceuticals has announced the database lock in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The company expects to release topline results in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:35 pm

Adial Pharmaceuticals (NASDAQ:ADIL) reported a Q2 EPS of $(0.59), showing a significant improvement from $(1.33) per share in the same period last year, marking a 55.64% increase.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:33 pm

Adial Pharmaceuticals (NASDAQ:ADIL) announced a collaboration with Boudicca Dx to advance the regulatory strategy for its companion diagnostic genetic test for AD04, a treatment for Alcohol Use Disorder. This collaboration aims to ensure the test meets FDA guidelines and supports the upcoming Phase 3 study.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 12:30 pm

Adial Pharmaceuticals has announced that Boudicca will support and advise the company on its companion diagnostic genetic test to ensure compliance with FDA guidelines.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:30 pm

Adial Pharmaceuticals has signed an agreement with Boudicca Dx to advance the regulatory strategy for a companion diagnostics genetic test for AD04.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:30 pm

Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of dosing in the pharmacokinetics study of AD04 for Alcohol Use Disorder. The study's topline results are expected in Q4 2024, marking a significant milestone towards initiating Phase 3 clinical trials.

Portfolio Pulse from Vandana Singh

August 07, 2024 | 12:30 pm

Adial Pharmaceuticals has announced that it expects to release topline results during the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.